[go: up one dir, main page]

ES8707974A1 - Procedimiento para la obtencion de un peptido - Google Patents

Procedimiento para la obtencion de un peptido

Info

Publication number
ES8707974A1
ES8707974A1 ES550911A ES550911A ES8707974A1 ES 8707974 A1 ES8707974 A1 ES 8707974A1 ES 550911 A ES550911 A ES 550911A ES 550911 A ES550911 A ES 550911A ES 8707974 A1 ES8707974 A1 ES 8707974A1
Authority
ES
Spain
Prior art keywords
peptide
obtaining
procedure
peptidoamide
protective groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES550911A
Other languages
English (en)
Other versions
ES550911A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES550911A0 publication Critical patent/ES550911A0/es
Publication of ES8707974A1 publication Critical patent/ES8707974A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

METODO DE OBTENER UN PEPTIDO. CONSISTE EN DISOCIAR LOS GRUPOS PROTECTORES DE PEPTIDOAMIDA O N-ACILADO DE UNA PEPTIDOAMIDA, EN UN MEDIO SOLVOLITICO, ENTRE 0 Y 50JC, PARA OBTENER UN PEPTIDO DE FORMULA (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. LOS RESTOS DE CISTEINA DESARROLLAN FUENTES DE DISULFURO INTRAMOLECULARES, Y LOS GRUPOS PROTECTORES PROTEGEN A LOS GRUPOS FUNCIONALES. SE UTILIZAN EN EL SECTOR FARMACEUTICO COMO COMPUESTOS INTERMEDIOS.
ES550911A 1985-01-16 1986-01-15 Procedimiento para la obtencion de un peptido Expired ES8707974A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH18885 1985-01-16

Publications (2)

Publication Number Publication Date
ES550911A0 ES550911A0 (es) 1987-09-01
ES8707974A1 true ES8707974A1 (es) 1987-09-01

Family

ID=4181264

Family Applications (2)

Application Number Title Priority Date Filing Date
ES550911A Expired ES8707974A1 (es) 1985-01-16 1986-01-15 Procedimiento para la obtencion de un peptido
ES557315A Expired ES8802161A1 (es) 1985-01-16 1987-01-14 Procedimiento para la obtencion de peptidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES557315A Expired ES8802161A1 (es) 1985-01-16 1987-01-14 Procedimiento para la obtencion de peptidos

Country Status (12)

Country Link
US (1) US4720483A (es)
EP (1) EP0188400B1 (es)
JP (1) JPH0780908B2 (es)
AT (1) ATE78040T1 (es)
CA (1) CA1339365C (es)
DE (1) DE3685885D1 (es)
DK (1) DK17986A (es)
ES (2) ES8707974A1 (es)
FI (1) FI86547C (es)
GR (1) GR860081B (es)
IE (1) IE58190B1 (es)
PT (1) PT81837B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221518A (en) * 1984-12-14 1993-06-22 Mills Randell L DNA sequencing apparatus
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
DE3888357T2 (de) * 1987-06-22 1994-09-15 Merck & Co Inc Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen.
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
AU629552B2 (en) * 1988-06-16 1992-10-08 Teijin Limited S-sulfonated calcitonin derivatives
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
GB8829432D0 (en) * 1988-12-15 1989-02-01 Celltech Ltd Enzymatic process
EP0448513A3 (en) * 1990-03-21 1991-12-27 Japat Ltd Process for production of peptidylglycine alpha-hydroxylating monooxygenase and use thereof
WO1993002697A1 (en) * 1991-08-08 1993-02-18 Amylin Pharmaceuticals, Inc. Production of peptide amides
US5569604A (en) * 1993-09-03 1996-10-29 The University Of Iowa Research Foundation Calcitonin/calcitonin gene related peptide enhancer element and associated DNA binding proteins
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
US20050042647A1 (en) * 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US20040203024A1 (en) * 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US7812149B2 (en) * 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU725954B2 (en) * 1996-08-15 2000-10-26 Board Of Trustees Of Southern Illinois University, The Enhancement of antimicrobial peptide activity by metal ions
DE19652033A1 (de) * 1996-12-13 1998-06-18 Irmgard Dr Med Guertner Neuropeptid (CGRP) als Modulator zur Zelldifferenzierung und Proliferation
WO2004044136A2 (en) * 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2’-modified nucleosides for use in gene modulation
US20060241072A1 (en) * 2003-06-20 2006-10-26 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
EP1703916A2 (en) 2004-01-13 2006-09-27 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
JP2007517912A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド 心脈管および腎臓の適応症のための制御放出ｃｇｒｐ送達組成物
WO2005070444A2 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
US8569474B2 (en) * 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
JP2008501693A (ja) * 2004-06-03 2008-01-24 アイシス ファーマシューティカルズ、インク． 遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
JP4884193B2 (ja) * 2006-12-15 2012-02-29 ヤマハ発動機株式会社 船舶
US8835379B2 (en) 2009-10-30 2014-09-16 Novo Nordisk A/S Derivatives of CGRP
CA2846234A1 (en) * 2011-08-22 2013-02-28 Suganit Systems, Inc. Production of bio-butanol and related products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374618A (en) * 1983-06-15 1994-12-20 Celltech Limited Calcitonin peptides, and gene related pharmaceutical compositions
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
GB8327346D0 (en) * 1983-10-12 1983-11-16 Morris H R Peptide
US4549986A (en) * 1983-12-23 1985-10-29 The Salk Institute For Biological Studies Human CGRP

Also Published As

Publication number Publication date
ES8802161A1 (es) 1988-04-01
CA1339365C (en) 1997-08-26
US4720483A (en) 1988-01-19
JPH0780908B2 (ja) 1995-08-30
FI860153A0 (fi) 1986-01-13
EP0188400B1 (de) 1992-07-08
GR860081B (en) 1986-04-29
IE860116L (en) 1986-07-16
DE3685885D1 (de) 1992-08-13
ES550911A0 (es) 1987-09-01
ATE78040T1 (de) 1992-07-15
DK17986D0 (da) 1986-01-15
JPS61172899A (ja) 1986-08-04
FI86547C (fi) 1992-09-10
PT81837A (en) 1986-02-01
IE58190B1 (en) 1993-07-28
EP0188400A3 (en) 1988-08-31
ES557315A0 (es) 1988-04-01
DK17986A (da) 1986-07-17
EP0188400A2 (de) 1986-07-23
FI86547B (fi) 1992-05-29
FI860153L (fi) 1986-07-17
PT81837B (pt) 1988-05-27

Similar Documents

Publication Publication Date Title
ES8707974A1 (es) Procedimiento para la obtencion de un peptido
SE8602723L (sv) Tiazoler, deras framstellning och farmaceutiska kompositioner innehallande dem
ES2108425T3 (es) Analogos de atp sustituidos con n-alquilo-2.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2086371T3 (es) 1,3-oxatiolanos sustituidos con propiedades antiviricas.
ES2072959T3 (es) Derivados de aminoacido.
MX9304360A (es) Derivados de rapamicina y composiciones farmaceuticas de los mismos.
ES2147230T3 (es) Derivados de aminoacidos, medicamentos que contienen a estos compuestos y procedimiento para su preparacion.
ES8602022A1 (es) Un procedimiento para preparar un derivado de 4'-dimetil-4-epipodofilotoxina
CY1109581T1 (el) Εστερες στη θεση 20 των καμπτοθεκινων
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CY1108793T1 (el) Καμπτοθεκινες με τροποποιημενο λακτονικο δακτυλιο
PT83535B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de aminoacidos
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
ES2167021T3 (es) Derivados de acido 4-bifenil-4-hidroxibutirico sustituidos como inhibidores de metaloproteasa de matriz.
AR006991A1 (es) Analogo hidrosoluble de 20(s)- camptotecina, una composicion farmaceutica que los contiene, una medicina para el tratamiento del cancer, leucemia oestados relacionados con el hiv, el uso de dichos compuestos y un procedimiento para su preparacion
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
MX9301404A (es) Derivados de 2-oxoquinolina, procedimiento para su preparacion, preparado farmaceutico que los contiene y procedimiento para la obtencion de tal preparado farmaceutico.
ES2032752T3 (es) Procedimiento de preparacion de derivados de la 1-bencenosulfonil-2-oxo-5-alcoxi-pirrolidina.
AR025351A1 (es) Agonistas retinoides selectivos par
ES2182090T3 (es) Nuevos derivados de pirrol.
ES2038163T3 (es) Procedimiento para preparar 1,3-dioxolanos trisustituidos en 2,4,4 y tetrasustituidos en 2,2,4,4.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970612